To evaluate the efficacy of submucosal injection of triamcinolone acetonide for the treatment of type II/III interstitial cystitis/bladder pain syndrome. A retrospective analysis of the clinical data of type II/III interstitial cystitis/bladder pain syndrome patients treated in our department from April 2016 to August 2018 was conducted, and changes in International Prostate Symptom Scores and the Pelvic Pain and Urgency/Frequency symptom scale after surgery were evaluated to explore factors that may affect patient outcomes. A total of 27 female patients and 8 male patients were enrolled, with type II patients accounting for 62.9% of the sample, and the median follow-up duration was 31 months (range: 12–40 months). Twenty-two patients (74.3%) had significantly improved questionnaire scores at 4 weeks postoperatively. Treatment efficacy was sustained for at least 1 year in 15 patients, and persistent effectiveness was noted in 10 (28.6%) patients. Patients with an advanced age (p = 0.015), high pain scores (p = 0.040), and higher International Prostate Symptom Scores (p = 0.037) and Pelvic Pain and Urgency/Frequency symptom scale scores (p = 0.020) were more likely to benefit from submucosal injection of triamcinolone acetonide. Gender, disease duration, and the presence of Hunner’s lesions had no predictive value for treatment outcomes. Submucosal injection of triamcinolone acetonide can improve the clinical symptoms and quality of life in both men and women with type II/III interstitial cystitis/bladder pain syndrome. Patients with an advanced age and more severe interstitial cystitis/bladder pain syndrome related symptoms may benefit more from triamcinolone acetonide injection.

中文翻译：

---

黏膜下注射曲安奈德治疗Ⅱ/Ⅲ型间质性膀胱炎/膀胱疼痛综合征的临床疗效

评价粘膜下注射曲安奈德治疗II / III型间质性膀胱炎/膀胱疼痛综合征的疗效。回顾性分析我科2016年4月至2018年8月收治的II / III型间质性膀胱炎/膀胱疼痛综合征患者的临床资料，术后国际前列腺症状评分以及盆腔疼痛和尿急/频度症状量表的变化对手术进行了评估，以探讨可能影响患者预后的因素。总共招募了27位女性患者和8位男性患者，其中II型患者占样本的62.9％，中位随访时间为31个月（范围：12-40个月）。术后4周，有22名患者（74.3％）的问卷调查得分显着提高。15名患者的治疗效果至少持续了1年，而10名患者（28.6％）的疗效持续存在。高龄（p = 0.015），高疼痛评分（p = 0.040）和较高的国际前列腺症状评分（p = 0.037）和骨盆疼痛和尿急/频率症状量表评分（p = 0.020）的患者得益于曲安奈德的粘膜下注射。性别，疾病持续时间和洪纳氏病灶的存在对治疗结果没有预测价值。粘膜下注射曲安奈德可以改善患有II / III型间质性膀胱炎/膀胱疼痛综合征的男性和女性的临床症状和生活质量。